GMM Pfaudler posts Q3 FY24 consolidated PAT at Rs. 31.72 Cr

GMM Pfaudler has reported total income of Rs. 848.28 crores during the period ended December 31, 2023

Industry’s reaction to Union Budget 2024-25

Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry

Max Healthcare Institute Ltd Q3 FY24 consolidated profit up at Rs. 289.34 Cr

Max Healthcare Institute has reported total income of Rs. 1380.99 crores during the period ended December 31, 2023

Dabur India posts Q3 FY24 consolidated PAT at Rs. 514.22 Cr

Dabur India has reported total income of Rs. 3382.43 crores during the period ended December 31, 2023

Vimta Labs posts Q3 FY24 consolidated PAT at Rs. 10.13 Cr

Vimta Labs has reported total income of Rs. 82.57 crores during the period ended December 31, 2023

Morepen Laboratories reports Q3 FY24 consolidated PAT at Rs. 31.99 Cr

Morepen Laboratories has reported total income of Rs. 448.62 crores during the period ended December 31, 2023

Lupin Digital Health introduces digital therapeutics certificate for Cardiologists in India in collaboration with ACC

Sun Pharmaceutical Industries Q3 FY24 consolidated PAT up at Rs. 2,560.54 Cr

Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023

Eastman, SEG collaborate to launch INVU 10th anniversary collection with Tritan Renew

Tritan Renew, which is made with 50% certified recycled content derived from hard-to-recycle waste, performs like virgin-quality material

EMA validates Type II variation application for enfortumab vedotin with pembrolizumab for treatment of bladder cancer

Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival